Castrate-resistant prostate cancer: the future of antiandrogens

Pshezhetskiy, Dmitry, Alshaker, Heba and Stebbing, Justin (2014) Castrate-resistant prostate cancer: the future of antiandrogens. Trends in Urology & Men’s Health, 5 (1). ISSN 2044-3749

[thumbnail of Accepted manuscript]
PDF (Accepted manuscript) - Accepted Version
Download (269kB) | Preview


Prostate cancer is the most common non-cutaneous cancer in North American and European men and the second leading cause of male cancer-related death [1]. The lifetime probability of developing prostate cancer in the UK is 14% [1] and in 2010 there were there were 40,975 new cases, accounting for 10,721 deaths [2]. Prostate cancer is associated with many risk factors, including age, family history, ethnicity, diet, and weight and although it is estimated that not more than 5% of all prostate cancer cases are hereditary, family history is appropriately considered a relevant risk factor. Many genetic changes have been associated with prostate cancer, including mutations in P53, P21, and P73 and tumour suppressor genes [3].

Item Type: Article
Uncontrolled Keywords: sdg 3 - good health and well-being ,/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being
Faculty \ School: Faculty of Medicine and Health Sciences > Norwich Medical School
UEA Research Groups: Faculty of Medicine and Health Sciences > Research Centres > Metabolic Health
Related URLs:
Depositing User: Pure Connector
Date Deposited: 11 Jan 2017 00:06
Last Modified: 06 Jun 2024 14:57
DOI: 10.1002/tre.371


Downloads per month over past year

Actions (login required)

View Item View Item